Skip to main content

Table 3 RFS and pCR rates for 42 patients classified by clinical and genetic characteristics

From: Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

 

Response to neoadjuvant chemotherapy

Relapse-free survival

 

pCR

No pCR

P-value

No. of Patients (No. of events)

3-year estimates

95% CI

P-value

All patients

20

17

 

42 (12)

0.72

0.55-0.89

 

Response to neoadjuvant chemotherapy

       

 pCR (grade 3)

   

20 (4)

0.73

0.52-0.93

0.764

 No pCR (grade 0~2)

   

17 (5)

0.86

0.67-1.04

 

Hormone receptors

       

 Positive

8

14

0.009

25 (7)

0.76

0.58-0.95

0.914

 Negative

12

3

 

17 (5)

0.69

0.42-0.95

 

HER2 copy numbers

       

 ≤ 2.0

1

6

0.019

8 (5)

0.57

0.20-0.94

0.095

 > 2.0

19

11

 

34 (7)

0.78

0.62-0.94

 

Wild-type HER2 mRNA

       

 < 400

8

9

0.208

20 (8)

0.61

0.40-0.83

0.022

 ≥ 400

11

5

 

17 (2)

0.92

0.76-1.07

 

∆16HER2 mRNA

       

 < 4.5

5

8

0.020

17 (5)

0.72

0.50-0.93

0.314

 ≥ 4.5

15

4

 

20 (5)

0.75

0.53-0.96

 

Percentages of ∆16HER2 mRNA

       

 < 2.4%

17

11

0.581

31 (6)

0.79

0.63-0.94

0.039

 ≥ 2.4%

5

1

 

6 (4)

0.50

0.10-0.90

 

PIK3CA

       

 Wild-type

18

14

0.498

36 (9)

0.79

0.64-0.94

0.171

 Mutated

2

3

 

6 (3)

0.42

−0.02-0.85

 

PIK3CA

       

 Wild-type + Normal + Loss + UPD

16

9

0.08

28 (6)

0.85

0.70-1.01

0.041

 Mutated + Gain

4

8

 

14 (6)

0.56

0.29-0.83

 

PTEN

       

 Normal + Gain + UPD

20

12

0.009

37 (11)

0.73

0.56-0.89

0.705

 Loss

0

5

 

5 (1)

0.80

0.45-1.15

 

INPP4B

       

 Normal + Gain + UPD

17

16

0.373

36 (8)

0.79

0.64-0.94

0.095

 Loss

3

1

 

6 (4)

0.50

0.10-0.90

 

PI3KCA , PTEN, INPP4B

       

 No aberrations*

14

6

0.086

22 (4)

0.81

0.60-1.01

0.195

 Aberrations**

6

11

 

20 (8)

0.67

0.45-0.89

 

DEK

       

 Normal

13

14

0.236

28 (5)

0.88

0.75-1.01

0.006

 Gain

7

3

 

14 (7)

0.44

0.14-0.75

 

FGFR1

       

 Normal + Loss + UPD

17

9

0.035

29 (9)

0.75

0.48-0.86

0.641

 Gain

3

8

 

13 (3)

0.92

0.76-1.07

 

CCND1

       

 Normal + Loss

11

12

0.33

25 (4)

0.84

0.68-1.01

0.043

 Gain

9

5

 

17 (8)

0.58

0.33-0.84

 

FOXA1

       

 Normal + UPD

15

13

0.917

30 (6)

0.80

0.64-0.96

0.012

 Gain

5

4

 

12 (6)

0.60

0.29-0.91

 

CDH3

       

 Normal + Loss + UPD

19

14

0.217

37 (8)

0.79

0.64-0.94

0.009

 Gain

1

3

 

5 (4)

0.40

−0.03-0.83

 

BIRC5

       

 Normal + Loss + UPD

14

13

0.659

27 (5)

0.82

0.66-0.98

0.005

 Gain

6

4

 

15 (7)

0.56

0.25-0.88

 

MYBL2

       

 Normal + Loss

18

10

0.028

30 (7)

0.80

0.64-0.96

0.053

 Gain

2

7

 

12 (5)

0.58

0.24-0.91

 

AIB1

       

 Normal + Loss

18

11

0.063

31 (7)

0.81

0.65-0.96

0.017

 Gain

2

6

 

11 (5)

0.52

0.15-0.89

 
  1. CI, confidence interval; *No aberrations, wild-type and a normal copy of PIK3CA, a normal copy, gain or UPD of PTEN or INPP4B; **Aberrations, mutated and/or gain of PIK3CA, and loss of PTEN or INPP4B.